Overview of Executive Compensation system

(1) The Decision Policy regarding the Content of Individual Compensations of Directors

The Company has established a policy regarding decisions of the content of individual compensations for Directors at the Board meeting held on May 13, 2021 and has revised a part of the content at the Board meeting held on May 19, 2022 and November 30, 2023. The outline is as follows.

1) Compensation Policy

Compensations to Directors are designed based on the following ideas.

  • Compensation system with a compensation level that can secure and maintain excellent human resources
  • Compensation system that motivates sustainable growth over the medium to long term and contributes to the increase of the value of the Company and shareholder value
  • A transparent, fair and rational compensation system accountable to stakeholders

2) Level of Compensations

The level of compensations to Directors is set aiming to provide the high level compensations in the industrial circle, referring to the levels of other companies learned from the surveys of external specialist institutions. Specifically, the Company will mainly compare companies within the top 100 companies by market capitalization among the companies listed on the Tokyo Stock Exchange, and also refer to the levels of major domestic pharmaceutical companies.

3) Composition of compensations

Directors (excluding Outside Directors)

It is designed to encourage management efforts from a short-term to medium-long-term perspective and appropriately to be able to reward the results by the composition of four compensations such as basic, fixed compensation, annual performance-based bonuses, which is a variable compensation serving as short-term incentive, and restricted share-based compensation and medium-term performance-based share compensation serving as long-term incentive. Retirement benefit system is not adopted.

Outside Directors

Compensation to Outside Directors who are in charge of management oversight and are not in the position to take charge of business execution is only basic, fixed compensation. Incentive bonuses and retirement benefit system are not adopted.

4) Ratio of the composition of compensations

The composition of compensations to Representative Director, President and CEO is designed to have its ratio of 40% as basic compensation, 30% as annual performance-based bonuses, 15% as restricted share-based compensation and 15% as medium-term performance-based share compensation when achieving the performance target of 100%.

The ratio of the composition of compensations of other Directors (excluding Outside Directors) will be determined in consideration of the responsibilities and the level of compensation according to the ratio of composition of compensation of Representative Director, President and CEO.

Compensation to Outside Directors is only basic, fixed compensation.

An enlargeable image opens in a separate window

5) Basic compensation

Basic compensation to Directors shall be paid on one regular day of each month during their tenure, and the amount of individual compensation is determined according to the compensations policy and the level of compensations.

6) Annual performance-based bonuses (short-term incentive)

The amount of annual performance-based bonuses, which are short-term incentive remuneration, will be decided according to the degree of achievement of the earnings forecasts announced at the beginning of the fiscal year about profit attributable to owners of the Company, revenue and core operating profit ratio, and the evaluation of goals and tasks which each Director set at the beginning of the fiscal year.
The formula for calculating the amount of payment, and the evaluation ratio and mechanism of annual performance-based bonuses are as follows.

  • 1. Calculation formula for annual performance-based bonus

  • Bonus payment amount = Standard amount by position * Achievement of annual targets (revenue + core operating profit ratio + profit attributable to owners of the Company)* performance evaluation

  • 2. Achievement of annual targets (evaluation ratio and mechanism)

Index for the achievement of annual targets Evaluation ratio Evaluation coefficient fluctuation range Targets (set with the following as a guide)
Revenue 10% 0%-200% Upper limit: Target * 105%
Target: Expected value announced at the beginning of the fiscal year
Lower limit: Target * 95%
Core operating profit ratio 10% 0%-200% Upper limit: Target * 115%
Target: Expected value announced at the beginning of the fiscal year
Lower limit: Target * 85%
Profit attributable to owners of the Company 80% 0%-200% Upper limit: Target * 120%
Target: Expected value announced at the beginning of the fiscal year
Lower limit: Target * 80%
Total 100% 0%-200%

An enlargeable image opens in a separate window

3. Performance evaluation

It will be converted into a coefficient and calculated according to the degree of achievement of each Director’s goals and tasks set at the beginning of the fiscal year.

  1. The performance evaluation of the Executive Chairperson and the President will be determined after deliberation at a joint meeting of the Nomination Committee and the Compensation Committee.
  2. For other Directors, the evaluation decided by CEO after deliberation at the performance meeting shall be applied. The evaluation results of Directors will be reported to the Compensation Committee.
Index Coefficient Evaluation method
Executive Chairperson / President Company-wide tasks such as R&D progress Successor training, etc. 50%-150% Decided after deliberation at a joint meeting of the Nomination Committee and the Compensation Committee
Other Directors Department (individual) goals 80%-120% Performance evaluation (CEO)

7) Restricted share-based compensation (Long-term incentives)

The Company grants, every year in principle, shares with transfer restriction until the time immediately after resignation or retirement of a Director. The objective of the system is to give incentives to sustainably increase the value of the Company and to promote sharing the same value between shareholders and Directors for as long as possible by having the restricted shares. The total number of the ordinary shares of the Company to be issued or disposed of is 240 thousand shares or less per year (if a share split of the Company’s ordinary shares (including a gratis allotment of the Company’s ordinary shares) or a share consolidation occurs, or if there is any other reason that requires adjustment of the total number, Daiichi Sankyo will adjust the number in a reasonable range as necessary according to the split or consolidation ratio.).

When restricted share-based compensation is paid, monetary compensation receivables will be paid to Directors based on a resolution of the Board of the Company, and Directors will pay all of the paid monetary compensation receivables as in-kind contribution assets of the Company’s ordinary shares and will be issued them.

When delivering the Company’s ordinary shares, a restricted share allotment agreement will be concluded between the Company and each Director, and Directors shall not freely transfer, set security interests or otherwise dispose of the Company’s ordinary shares allotted under the allotment agreement for a certain period of time specified in the allotment agreement.

In the allotment agreement, (1) if a Director of the Company retires or resigns during the transfer restriction period, the Company shall acquire all of the restricted shares without consideration unless otherwise such the retirement or resignation is admitted by the Board that it has justifiable reasons such as expiration of terms of office, death or others, and (2) if a Director retires or resigns due to expiration of term, death or other reasons deemed justified by the Board during the service provision period, the Company shall rationally adjust the number of shares for which the restrictions will be released and the timing of the release as necessary and acquire the restricted shares which the restrictions will not be released free of charge, will be included.

The number of restricted share-based compensation to be delivered shall be the number of shares of the Company’s ordinary shares, which is the amount of restricted share-based compensation for each position divided by the closing price of the market price of the Company’s ordinary share on the day before the allotment resolution by the Board.

8) Medium-term performance-based share compensation (Long-term incentives)

Medium-term performance-based share compensation, which is a long-term incentive compensation, will be a trust-type share compensation system that has the nature of performance share (performance-based share compensation) for Directors (excluding Outside Directors) and the Corporate Officers (hereinafter, “the Target Directors & Officers.”) as compensation based on the achievement of the performance of the mid-term business plan in order to promote management with an emphasis on increasing shareholder value over the medium to long term.

The trust period for the fiscal year covered by the mid-term business plan (hereinafter, the “Target Period,” and the initial Target Period is 5-Year Business Plan (fiscal 2021-fiscal 2025)) will be set.

The number of shares of the Company, etc. to be delivered, etc. to the Target Directors & Officers shall be determined at a certain time every year based on share delivery points calculated by multiplying the number of points accumulated over a Target Period, which are awarded according to their position, by the performance-based coefficient. The performance-based coefficient shall be determined within the range between 0% and 200% according to the degree of achievement of targets of Daiichi Sankyo’s performance indicators set forth for the final fiscal year of the Target Period (For the initial Target Period, revenue, core operating profit ratio before research and development expenses, ROE, research and development progress, ESG indicators, and relative TSR set forth in Daiichi Sankyo’s 5-Year Business Plan announced in fiscal 2021 have been adopted.), and one ordinary share in Daiichi Sankyo per point shall be delivered. During the trust period, if a share split of the Company’s ordinary shares (including a gratis allotment of the Company’s ordinary shares) or a share consolidation occurs, or if there is any other reason that requires adjustment of the number of points, Daiichi Sankyo will adjust the number of points in a reasonable range as necessary according to the split or consolidation ratio. The total number of ordinary shares, etc. of the Company to be delivered to the Target Directors & Officers during the Target Period will be limited to the number obtained by multiplying the maximum number of 0.5 million shares per fiscal year by the number of fiscal years of the Target Period (The initial Target Period is 2.5 million shares for the five fiscal years.). As a general rule, when the Target Directors & Officers receive the Company’s shares, etc., after their retirement, 50% of the shares to be delivered will be converted into money and be provided for the purpose of allocating to tax payment funds such as withholding income tax. Shares and monetary payments will be provided through the executive compensation BIP (Board Incentive Plan) trust of Mitsubishi UFJ Trust and Banking Corporation.

With justifiable reason, when it is not possible to establish the trust, amend the trust agreement, make additional contribution to the Trust, or when Target Directors & Officers are non-resident of Japan, or with any other justifiable reason, that delivery of the Company’s Shares, etc. to Target Directors & Officers from the trust is not possible, the Company may, within the upper limit of amount of money to be contributed by the Company, make monetary payments of the amount reasonably calculated based on the number of the Company’s Shares, etc. that should be delivered in accordance with the plan and share price, etc., to Target Directors & Officers.

Index for the achievement of targets Evaluation ratio Evaluation coefficient fluctuation range Targets (set with the following as a guide)
Revenue 20% 0%-200% Upper limit: Target * 110%
Target: Expected value announced about 5-year business plan
Lower limit: Target * 90%
Core operating profit ratio before research and development expenses 20% 0%-200% Upper limit: Target * 120%
Target: Expected value announced about 5-year business plan
Lower limit: Target * 80%
ROE 20% 0%-200% Upper limit: Target * 140%
Target: Expected value announced about 5-year business plan
Lower limit: Target * 60%
Research and development progress 15% 0%-200% Research and development achievements (number of new indications for 3ADC on the market, pipeline value in the early and late stages)
ESG indicators 10% 0%-200% Evaluation based on Dow Jones Sustainability Indices, FTSE Russell or Access to Medicine
Relative TSR 15% 0%-200% Upper limit: Comparison result with
TOPIX including dividend * 150%
Target: Comparison result with
TOPIX including dividend * 100%
Lower limit: Comparison result with
TOPIX including dividend * 50%
Total 100% 0%-200%

9) Clawback provision

Daiichi Sankyo will set forth a clawback clause that can request for the refund of part or all of the compensation received for annual performance-based bonuses and medium-term performance-based share compensation by the resolution of the Board after consultation with the Compensation Committee in the event that a material accounting error or fraud, or record of a significant impairment loss occurs.
This clause will be applied from the fiscal 2021 annual performance-based bonus and medium-term performance-based share compensation and will be applied for all periods thereafter.

10) Compensation governance and decision-making process

  • The Compensation Committee has been established as an advisory body to the Board to ensure the appropriateness of compensation for Directors and the transparency of the decision-making process. The Compensation Committee consists of only Outside Directors, with one Outside Audit & Supervisory Board Member participating as an observer, and the chairperson is appointed by mutual appointment of the members.
  • The Compensation Committee fully discusses the compensation policy, the level of compensations, the composition of the compensation, the ratio of the composition of compensations, Clawback provision, the compensation governance and decision-making process, amount of annual performance-based bonuses, allocation of restricted share, and result of medium-term performance-based share compensation. In addition, the Compensation Committee discusses and confirms the detailed design of indices for the achievement of each compensation, and also verifies the compensation levels for each position.
  • The amount of compensation for each individual Director of the Company is first deliberated by the Compensation Committee, and then based on the deliberation results, each type of the compensation will be determined by a resolution of the Board within the total amount of compensation resolved at the General Meeting of Shareholders.

As stated in the above policy, the Compensation Committee fully discusses the compensations policy, the level of compensations, the composition of the compensation, the ratio of the composition of compensations, Clawback provision, the compensation governance and decision-making process, amount of annual performance-based bonuses, allocation of restricted share, and result of medium-term performance-based share compensation. The content of individual compensation for Directors in the current fiscal year is also decided by the Board after being first deliberated by the Compensation Committee. We judge that the content of the Company’s compensation governance is in line with the above-mentioned policy regarding decisions of the content of individual compensation for Directors.

Total amount of consolidated compensation for each Director in fiscal 2023
Name (Position) Company Total amount of consolidated compensation and related payments by type
(Millions of JPY)
Total amount of compensation and related payments
(Millions of JPY)
Basic compensation Annual performance-based bonuses
(Non-monetary compensation)
Restricted share-based compensation
(Non-monetary compensation)
Medium-term performance-based share compensation
Sunao Manabe
(Representative Director, President and CEO)
Daiichi Sankyo Company, Limited 108 172 40 59 386
Hiroyuki Okuzawa
(Representative Director, President and COO)
Daiichi Sankyo Company, Limited 84 109 24 35 253
Shoji Hirashima
(Representative Director, Senior Executive Officer, Head of Japan Business Unit)
Daiichi Sankyo Company, Limited 57 69 16 24 169
Masahiko Ohtsuki
(Director, Senior Executive Officer, Head of Global DX Chief Digital Transformation Officer)
Daiichi Sankyo Company, Limited 51 61 14 21 148
Takashi Fukuoka
(Director, Senior Executive Officer, Head of Global Corporate Strategy Chief Strategy Officer)
Daiichi Sankyo Company, Limited 51 61 14 21 148
  • This report is only for those whose total consolidated compensation is 100 million yen or more.
  • The amount of “restricted share-based compensation” and “medium-term performance-based share compensation” above represents the amount recorded as expenses for restricted share-based compensation and medium-term performance-based share compensation in fiscal 2023.

(2) The Decision Policy regarding the Content of Individual Compensations of Audit & Supervisory Board Members

The outline of the decision policy regarding the content of individual compensations of Audit & Supervisory Board Members is as follows.

  • Compensation to Audit & Supervisory Board Members is only basic, fixed compensation in view of the role of oversight of management and no position to take charge of business execution.
  • The level of basic compensations is set aiming to provide high level compensations in the industrial sector, referring to the levels of other companies learned from the surveys of external specialist institutions. Specifically, a group of companies is selected for comparison from the top 100 listed companies on the Tokyo Stock Exchange with the largest market capitalization. The Company also refers to the levels of other leading domestic pharmaceutical companies.
  • The amount of the compensation for each Audit & Supervisory Board Member has been determined through the discussion and with the unanimous consent in the Audit & Supervisory Board meetings within the total amount of the compensation approved by the General Meeting of Shareholders.